Genedrive MT-RNR1 ID Kit to detect genetic variation and protect hearing in babies: early value appraisal.
The Genedrive MT-RNR1 ID Kit has potential benefits in identifying babies at risk of hearing loss from aminoglycoside due to the MT-RNR1 m.1555A>G variant, allowing for alternative antibiotics to be used instead. However, managing the risk of early access is important, including ensuring timely antibiotics, avoiding unnecessary use of alternative antibiotics, and confirming positive results. The economic evidence suggests cost-effectiveness, but upfront costs may be high. Data should be generated in centers with babies from different ethnicities to promote equality.
Recent Posts
Economic Impact of Fragmented Care: Tackling Obesity, Diabetes, and Cardiovascular Disease in Europe
Europe loses approximately €240 billion every year because of the interconnected burdens of obesity diabetes cardiovascular disease (EFPIA Guest Blog). Fragmented healthcare systems that treat late-stage complications instead of preventing disease progression are largely responsible for this mass...
Zanidatamab Biliary Cancer Therapy: Advancing Targeted Treatment for HER2-Positive Patients
Zanidatamab biliary cancer therapy has been recommended by NICE for routine use in the NHS to treat adults with unresectable locally advanced or metastatic HER2-positive biliary tract cancer who have received at least one prior line of systemic therapy.
Targeted Option for Rare Aggre...
Advancements in HIV Two-Drug Regimen: FDA Approves IDVYNSO for Virologically Suppressed Patients
The FDA has approved Merck’s HIV two-drug regimen, IDVYNSO™ (doravirine/islatravir), the first and only non-integrase strand transfer inhibitor (non-INSTI), tenofovir-free, once-daily complete regimen for adults with virologically suppressed HIV-1 infection.
First Non-INSTI, Tenofovi...